Keyword: Aurobindo Pharma
Immunomedics says it will meet with the FDA to discuss the CRL it got for manufacturing, while Teva has a new union agreement in place.
Terns names ex-Gilead executive as CMO; Spectrum sells all FDA-approved drugs to Aurobindo; Aslan's varlitinib fails in gastric cancer.
Spectrum is offloading seven drugs and transferring 40% of its total workforce to Aurobindo in a deal to "laser-focus" on novel cancer drugs.
Pfizer closes two Hospira plants in India; Gilead licenses Yuhan's NASH programs; Fujifilm is expanding its footprint in the U.S.
Aurobindo issued a voluntary recall of 80 lots of valsartan tablets due to the detection of trace amounts of an impurity.
Here are some of the other stories we're following today.
The Takeda-Shire deal passes investors; Sun suffers from a long list of allegations; J&J and Legend update CAR-T data.
Litigation is growing over tainted blood pressure medications with a class-action lawsuit now filed in Florida against Walmart and three drug companies that span the supply chain.
Ex-Roche scientists were charged with stealing trade secrets; Astellas invested in gene and cell therapy; Takeda touted growth in key focus areas.
The FDA says a probable cancer-causing ingredient has been found in yet another blood pressure treatment in the U.S.